TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
- PMID:9311998
- PMCID: PMC1170170
- DOI: 10.1093/emboj/16.17.5386
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Abstract
TRAIL is a member of the tumor necrosis factor (TNF) family of cytokines and induces apoptosis in a wide variety of cells. Based on homology searching of a private database, a receptor for TRAIL (DR4 or TRAIL-R1) was recently identified. Here we report the identification of a distinct receptor for TRAIL, TRAIL-R2, by ligand-based affinity purification and subsequent molecular cloning. TRAIL-R2 was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL-R2 contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL binds to recombinant cell-surface-expressed TRAIL-R2, and TRAIL-induced apoptosis is inhibited by a TRAIL-R2-Fc fusion protein. TRAIL-R2 mRNA is widely expressed and the gene encoding TRAIL-R2 is located on human chromosome 8p22-21. Like TRAIL-R1, TRAIL-R2 engages a caspase-dependent apoptotic pathway but, in contrast to TRAIL-R1, TRAIL-R2 mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. The existence of two distinct receptors for the same ligand suggests an unexpected complexity to TRAIL biology, reminiscent of dual receptors for TNF, the canonical member of this family.
Similar articles
- The receptor for the cytotoxic ligand TRAIL.Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM.Pan G, et al.Science. 1997 Apr 4;276(5309):111-3. doi: 10.1126/science.276.5309.111.Science. 1997.PMID:9082980
- Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis.Harper N, Hughes M, MacFarlane M, Cohen GM.Harper N, et al.J Biol Chem. 2003 Jul 11;278(28):25534-41. doi: 10.1074/jbc.M303399200. Epub 2003 Apr 29.J Biol Chem. 2003.PMID:12721308
- TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM.MacFarlane M, et al.Cancer Res. 2005 Dec 15;65(24):11265-70. doi: 10.1158/0008-5472.CAN-05-2801.Cancer Res. 2005.PMID:16357130
- TRAIL-induced signalling and apoptosis.MacFarlane M.MacFarlane M.Toxicol Lett. 2003 Apr 4;139(2-3):89-97. doi: 10.1016/s0378-4274(02)00422-8.Toxicol Lett. 2003.PMID:12628743Review.
- Cell death: TRAIL and its receptors.Golstein P.Golstein P.Curr Biol. 1997 Dec 1;7(12):R750-3. doi: 10.1016/s0960-9822(06)90000-1.Curr Biol. 1997.PMID:9382834Review.
Cited by
- Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CM, Kiely DG, Francis SE, Lawrie A.Hameed AG, et al.J Exp Med. 2012 Oct 22;209(11):1919-35. doi: 10.1084/jem.20112716. Epub 2012 Oct 15.J Exp Med. 2012.PMID:23071256Free PMC article.
- Quantitative Proteomics Analysis of Lytic KSHV Infection in Human Endothelial Cells Reveals Targets of Viral Immune Modulation.Gabaev I, Williamson JC, Crozier TWM, Schulz TF, Lehner PJ.Gabaev I, et al.Cell Rep. 2020 Oct 13;33(2):108249. doi: 10.1016/j.celrep.2020.108249.Cell Rep. 2020.PMID:33053346Free PMC article.
- Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.Qiao C, Hu M, Guo L, Lv M, Lin Z, Geng J, Lang X, Li X, Li Y, Ma Y, Feng J, Shen B.Qiao C, et al.BMC Immunol. 2012 Jul 12;13:40. doi: 10.1186/1471-2172-13-40.BMC Immunol. 2012.PMID:22788777Free PMC article.
- Reovirus-induced apoptosis is mediated by TRAIL.Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, Tyler KL.Clarke P, et al.J Virol. 2000 Sep;74(17):8135-9. doi: 10.1128/jvi.74.17.8135-8139.2000.J Virol. 2000.PMID:10933724Free PMC article.
- A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.Zhang S, Zheng C, Zhu W, Xiong P, Zhou D, Huang C, Zheng D.Zhang S, et al.Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.Theranostics. 2019.PMID:31410224Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases